Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus

Antiviral Research

Volumn 96, Issue 3, 2012, Pages 296-304

  Goswami, R ^a   Gershburg, S ^a   Satorius, A ^a   Gershburg, E ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EBV BGLF4 protein kinase; Epstein Barr virus (EBV); Protein kinase inhibitors (PKI); Signal transduction; Viral reactivation

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 5 IODOTUBERCIDIN; ACICLOVIR; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR ASSOCIATED TYROSINE KINASE INHIBITOR; ERBSTATIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; I KAPPA B; K 252A; KENPAULLONE; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR ASSOCIATED TYROSINE KINASE INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE INHIBITOR; ROTTLERIN; STAUROSPORINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; WORTMANNIN;

ARTICLE; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; GENE DOSAGE; LYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REACTION TIME; SIGNAL TRANSDUCTION; VIRUS GENE; VIRUS INHIBITION; VIRUS REACTIVATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BUTADIENES; CARBAZOLES; CELL LINE, TUMOR; CELL SURVIVAL; GENOME, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; INDOLE ALKALOIDS; MAP KINASE SIGNALING SYSTEM; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; NITRILES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SF9 CELLS; STAUROSPORINE; VIRAL PROTEINS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4;

EID: 84869102865     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.09.021     Document Type: Article

References (66)

1. Adamson A.L., Kenney S.C. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Virology 1998, 251:187-197.
2. Arcaro A., Wymann M.P. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J. 1993, 296(Pt. 2):297-301.
3. Asai R., Kato A., Kato K., Kanamori-Koyama M., Sugimoto K., Sairenji T., Nishiyama Y., Kawaguchi Y. Epstein-Barr virus protein kinase BGLF4 is a virion tegument protein that dissociates from virions in a phosphorylation-dependent process and phosphorylates the viral immediate-early protein BZLF1. J. Virol. 2006, 80:5125-5134.
4. Bahlis N.J., Miao Y., Koc O.N., Lee K., Boise L.H., Gerson S.L. N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. Leuk. Lymphoma 2005, 46:899-908.
5. Bertrand R., Solary E., O'Connor P., Kohn K.W., Pommier Y. Induction of a common pathway of apoptosis by staurosporine. Exp. Cell Res. 1994, 211:314-321.
6. Bilder G.E., Krawiec J.A., McVety K., Gazit A., Gilon C., Lyall R., Zilberstein A., Levitzki A., Perrone M.H., Schreiber A.B. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am. J. Physiol. 1991, 260:C721-C730.
7. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith I.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., Koszalka G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 2002, 46:2365-2372.
8. Brown H.J., Song M.J., Deng H., Wu T.T., Cheng G., Sun R. NF-kappaB inhibits gammaherpesvirus lytic replication. J. Virol. 2003, 77:8532-8540.
9. Chen M.R., Chang S.J., Huang H., Chen J.Y. A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro. J. Virol. 2000, 74:3093-3104.
10. Chin L.S., Murray S.F., Doherty P.F., Singh S.K. K252a induces cell cycle arrest and apoptosis by inhibiting Cdc2 and Cdc25c. Cancer Invest. 1999, 17:391-395.
11. Daibata M., Humphreys R.E., Takada K., Sairenji T. Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata. J. Immunol. 1990, 144:4788-4793.
12. Daikoku T., Shibata S., Goshima F., Oshima S., Tsurumi T., Yamada H., Yamashita Y., Nishiyama Y. Purification and characterization of the protein kinase encoded by the UL13 gene of herpes simplex virus type 2. Virology 1997, 235:82-93.
13. Dal Porto J.M., Gauld S.B., Merrell K.T., Mills D., Pugh-Bernard A.E., Cambier J. B cell antigen receptor signaling 101. Mol. Immunol. 2004, 41:599-613.
14. Darr C.D., Mauser A., Kenney S. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J. Virol. 2001, 75:6135-6142.
15. Davies A.H., Grand R.J., Evans F.J., Rickinson A.B. Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C. J. Virol. 1991, 65:6838-6844.
16. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351:95-105.
17. Fabbro D., Ruetz S., Bodis S., Pruschy M., Csermak K., Man A., Campochiaro P., Wood J., O'Reilly T., Meyer T. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000, 15:17-28.
18. Fan H., Gulley M.L. Epstein-Barr viral load measurement as a marker of EBV-related disease. Mol. Diagn. 2001, 6:279-289.
19. Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyk D.E., Pitts W.J., Earl R.A., Hobbs F., Copeland R.A., Magolda R.L., Scherle P.A., Trzaskos J.M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 1998, 273:18623-18632.
20. Feederle R., Kost M., Baumann M., Janz A., Drouet E., Hammerschmidt W., Delecluse H.J. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 2000, 19:3080-3089.
21. Fox T., Coll J.T., Xie X., Ford P.J., Germann U.A., Porter M.D., Pazhanisamy S., Fleming M.A., Galullo V., Su M.S., Wilson K.P. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Protein Sci. 1998, 7:2249-2255.
22. Gao X., Ikuta K., Tajima M., Sairenji T. 12-O-tetradecanoylphorbol-13-acetate induces Epstein-Barr virus reactivation via NF-kappaB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase. Virology 2001, 286:91-99.
23. Gershburg E., Hong K., Pagano J.S. Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication. Antimicrob. Agents Chemother. 2004, 48:1900-1903.
24. Gershburg E., Pagano J.S. Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the l-riboside benzimidazole 1263W94. J. Virol. 2002, 76:998-1003.
25. Gershburg E., Pagano J.S. Conserved herpesvirus protein kinases. Biochim. Biophys. Acta 2008, 1784:203-212.
26. Gershburg E., Raffa S., Torrisi M.R., Pagano J.S. Epstein-Barr virus-encoded protein kinase (BGLF4) is involved in production of infectious virus. J. Virol. 2007, 81:5407-5412.
27. Gershburg S., Murphy L., Marschall M., Gershburg E. Key motifs in EBV (Epstein-Barr virus)-encoded protein kinase for phosphorylation activity and nuclear localization. Biochem. J. 2010, 431:227-235.
28. Gschwendt M., Muller H.J., Kielbassa K., Zang R., Kittstein W., Rincke G., Marks F. Rottlerin, a novel protein kinase inhibitor. Biochem. Biophys. Res. Commun. 1994, 199:93-98.
29. Hamirally S., Kamil J.P., Ndassa-Colday Y.M., Lin A.J., Jahng W.J., Baek M.C., Noton S., Silva L.A., Simpson-Holley M., Knipe D.M., Golan D.E., Marto J.A., Coen D.M. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog. 2009, 5:e1000275.
30. Han Z., Pantazis P., Lange T.S., Wyche J.H., Hendrickson E.A. The staurosporine analog, Ro-31-8220, induces apoptosis independently of its ability to inhibit protein kinase C. Cell Death Differ. 2000, 7:521-530.
31. He Z., He Y.S., Kim Y., Chu L., Ohmstede C., Biron K.K., Coen D.M. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J. Virol. 1997, 71:405-411.
32. Hers I., Tavare J.M., Denton R.M. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett. 1999, 460:433-436.
33. Iwakiri D., Takada K. Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated Epstein-Barr virus activation. J. Immunol. 2004, 172:1561-1566.
34. Jacob T., Van den Broeke C., Favoreel H.W. Viral serine/threonine protein kinases. J. Virol. 2011, 85:1158-1173.
35. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912.
36. Kawaguchi Y., Kato K. Protein kinases conserved in herpesviruses potentially share a function mimicking the cellular protein kinase cdc2. Rev. Med. Virol. 2003, 13:331-340.
37. Kieff E., Rickinson A.B. Epstein-Barr virus and its replication. Fields Virology 2007, 2603-2654. Lippinkott-Williams & Wilkins, Philadelphia. fifth ed. D.M. Knipe, P.M. Howley (Eds.).
38. Kurosaki T., Shinohara H., Baba Y. B cell signaling and fate decision. Annu. Rev. Immunol. 2010, 28:21-55.
39. Lazdins J., Zompetta C., Grimaldi S., Barile G., Venanzoni M., Frati L., Faggioni A. TPA induction of Epstein-Barr virus early antigens in Raji cells is blocked by selective protein kinase-C inhibitors. Int. J. Cancer 1987, 40:846-849.
40. Liu S.F., Wang H., Lin X.C., Xiang H., Deng X.Y., Li W., Tang M., Cao Y. NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells. Cell Biol. Int. 2008, 32:1006-1013.
41. Marschall M., Stein-Gerlach M., Freitag M., Kupfer R., van den Bogaard M., Stamminger T. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J. Gen. Virol. 2002, 83:1013-1023.
42. Massillon D., Stalmans W., van de Werve G., Bollen M. Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor. Biochem. J. 1994, 299(Pt. 1):123-128.
43. McKenna J.P., Hanson P.J. Inhibition by Ro 31-8220 of acid secretory activity induced by carbachol indicates a stimulatory role for protein kinase C in the action of muscarinic agonists on isolated rat parietal cells. Biochem. Pharmacol. 1993, 46:583-588.
44. Mori T., Sairenji T. Functional role of phosphatidylinositol 3-kinase/Akt pathway on cell growth and lytic cycle of Epstein-Barr virus in the Burkitt's lymphoma cell line, P3HR-1. Virus Genes 2006, 32:327-334.
45. Murata T., Isomura H., Yamashita Y., Toyama S., Sato Y., Nakayama S., Kudoh A., Iwahori S., Kanda T., Tsurumi T. Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase. Virology 2009, 389:75-81.
46. Oussaief L., Ramirez V., Hippocrate A., Arbach H., Cochet C., Proust A., Raphael M., Khelifa R., Joab I. NF-kappaB-mediated modulation of inducible nitric oxide synthase activity controls induction of the Epstein-Barr virus productive cycle by transforming growth factor beta 1. J. Virol. 2011, 85:6502-6512.
47. Overton H.A., McMillan D.J., Klavinskis L.S., Hope L., Ritchie A.J., Wong-kai-in P. Herpes simplex virus type 1 gene UL13 encodes a phosphoprotein that is a component of the virion. Virology 1992, 190:184-192.
48. Palumbo G.A., Yarom N., Gazit A., Sandalon Z., Baniyash M., Kleinberger-Doron N., Levitzki A., Ben-Yehuda D. The tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. Cancer Res. 1997, 57:2434-2439.
49. Peng L., Wu T.T., Tchieu J.H., Feng J., Brown H.J., Li X., Qi J., Deng H., Vivanco I., Mellinghoff I.K., Jamieson C., Sun R. Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. J. Gen. Virol. 2010, 91:463-469.
50. Pierce J.W., Schoenleber R., Jesmok G., Best J., Moore S.A., Collins T., Gerritsen M.E. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 1997, 272:21096-21103.
51. Prichard M.N., Gao N., Jairath S., Mulamba G., Krosky P., Coen D.M., Parker B.O., Pari G.S. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 1999, 73:5663-5670.
52. Rickinson A.B., Kieff E.D. Epstein-Barr virus. Fields Virology 2007, 2655-2700. Lippinkott-Wiliams & Wilkins, Philadelphia. fifth ed. D.M. Knipe, P.M. Howley (Eds.).
53. Ringshausen I., Oelsner M., Weick K., Bogner C., Peschel C., Decker T. Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia 2006, 20:514-520.
54. Satoh T., Hoshikawa Y., Satoh Y., Kurata T., Sairenji T. The interaction of mitogen-activated protein kinases to Epstein-Barr virus activation in Akata cells. Virus Genes 1999, 18:57-64.
55. Schultz C., Link A., Leost M., Zaharevitz D.W., Gussio R., Sausville E.A., Meijer L., Kunick C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 1999, 42:2909-2919.
56. Takada K. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int. J. Cancer 1984, 33:27-32.
57. Takada K., Horinouchi K., Ono Y., Aya T., Osato T., Takahashi M., Hayasaka S. An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes 1991, 5:147-156.
58. Tovey M.G., Lenoir G., Begon-Lours J. Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 1978, 276:270-272.
59. Umezawa K., Hori T., Tajima H., Imoto M., Isshiki K., Takeuchi T. Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Lett. 1990, 260:198-200.
60. van Zeijl M., Fairhurst J., Baum E.Z., Sun L., Jones T.R. The human cytomegalovirus UL97 protein is phosphorylated and a component of virions. Virology 1997, 231:72-80.
61. Vlahos C.J., Matter W.F., Hui K.Y., Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 1994, 269:5241-5248.
62. Wang F.Z., Roy D., Gershburg E., Whitehurst C.B., Dittmer D.P., Pagano J.S. Maribavir inhibits Epstein-Barr viral transcription in addition to viral DNA replication. J Virol. 2009, 83:12108-12117.
63. Williams S.L., Hartline C.B., Kushner N.L., Harden E.A., Bidanset D.J., Drach J.C., Townsend L.B., Underwood M.R., Biron K.K., Kern E.R. In vitro activities of benzimidazole d- and l-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 2003, 47:2186-2192.
64. Wymann M.P., Bulgarelli-Leva G., Zvelebil M.J., Pirola L., Vanhaesebroeck B., Waterfield M.D., Panayotou G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 1996, 16:1722-1733.
65. Zacny V.L., Gershburg E., Davis M.G., Biron K.K., Pagano J.S. Inhibition of Epstein-Barr virus replication by a benzimidazole l-riboside: novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl-1H-benzimidazole. J. Virol. 1999, 73:7271-7277.
66. Zaharevitz D.W., Gussio R., Leost M., Senderowicz A.M., Lahusen T., Kunick C., Meijer L., Sausville E.A. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 1999, 59:2566-2569.